Chief Technology Officer, Xeltis BV, Netherlands
Martijn Cox is Co-Founder and CTO of Xeltis, a clinical-stage medical device company developing the first ever blood vessels and heart valves enabling cardiovascular restoration through a therapeutic approach called Endogenous Tissue Restoration (ETR). The porous structure of Xeltis’ restorative cardiovascular implants enables cardiovascular restoration by harnessing the body’s natural healing process to pervade it with new healthy tissue once implanted. As a new healthy blood vessel or heart valve made of patient’s own tissue forms around the structure of the implant and takes over functionality, the original implant gets absorbed in the body. Xeltis’ cardiovascular implants are made of bioabsorbable supramolecular polymers. To date, 28 children have received a Xeltis cardiovascular implant, during several small First-In-Human studies. Xeltis is currently working to bring first applications for adult patients to clinical stage.